Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis: pooled interim results for up to 3 years from the ASSURE study - Lawitz, E J; Trivedi, P J; Kowdley, K V; Gordon, S C; Bowlus, C L; Londoño Hurtado, M C; Hirschfield, G M; Gulamhusein, A; Demir, M; Crittenden, D B; Zhuo, S; Heusner, C; Levy, C (Zeitschrift für Gastroenterologie, 2025)